Lisa Rink, DO
Internal Medicine · Haddon Heights, NJNPI 1437101623
Payments from drug & device makers
Across 226 payments — averaging $14.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$806
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$387
- GSK$380
- Lilly USA, LLC$217
- AbbVie$215
- Astellas Pharma US Inc$210
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,12997%
- Education$1123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $806 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $387 |
| GSK | 35 | $380 |
| Lilly USA, LLC | 15 | $217 |
| AbbVie(2 entities) | 18 | $215 |
| Astellas Pharma US Inc | 9 | $210 |
| Novo Nordisk | 19 | $166 |
| Otsuka America Pharmaceutical, Inc. | 9 | $149 |
| Novartis | 8 | $121 |
| Amgen | 7 | $109 |
| Indivior Inc. | 4 | $63 |
| Shield Therapeutics Inc | 2 | $41 |
| Exact Sciences | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 4 | $38 |
| Antares Pharma, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $32 |
| Pfizer | 2 | $31 |
| Vertex | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Almatica Pharma LLC | 1 | $16 |
| Bayer | 1 | $16 |
| Insightec,inc | 1 | $16 |
| Abbott | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Merck | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| W. L. Gore & Associates, Inc. | 1 | $11 |
How this compares
$3,241 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $102,833 |
| OzempicSemaglutide | 63 | $82,879 |
| FarxigaDapagliflozin Propanediol | 52 | $58,887 |
| TrulicityDulaglutide | 43 | $54,662 |
| MounjaroTirzepatide | 20 | $40,569 |
| JanuviaSitagliptin Phosphate | 34 | $36,660 |
| Bydureon BciseExenatide Microspheres | 26 | $32,673 |
| XareltoRivaroxaban | 19 | $23,502 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $17,928 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $15,269 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $12,962 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $11,916 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,433 |
| LinzessLinaclotide | 15 | $8,971 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 61 | $6,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $31 | $102,833114 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $217 | $95,23163 claims |
| Novo NordiskOzempic | $166 | $82,87963 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $806 | $76,81575 claims |
| MerckJanuvia, Janumet | $12 | $48,57645 claims |
| Johnson & JohnsonXarelto | $12 | $23,50219 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $380 | $15,35228 claims |
| AbbVieLinzess, Synthroid | $215 | $12,07244 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $19 | $6,19661 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Haddon Heights
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.